

**Announcement
14 April 2014****Coloplast – transactions in connection with share buy-back programme**

As mentioned in Announcement No. 2/2014 Coloplast has initiated the first part of the share buy-back programme totalling up to DKK 1bn. This part of the programme of DKK500m is expected to take place from 3 March, 2014 to 31 August, 2014 at the latest.

The following transactions have been executed during the period 7 April - 11 April 2014:

Date	Number of shares	Buying price	Amount DKK
7 April 2014	15,000	435.9000	6,538,500
8 April 2014	10,000	432.7000	4,327,000
9 April 2014	2,000	434.7000	869,400
10 April 2014	10,000	429.8000	4,298,000
11 April 2014	20,000	422.0000	8,440,000
Accumulated until now under the programme	389,000	437,4440	170,165,700

Henceforth, Coloplast owns 8,910,867 own B shares of DKK 1 equal to 4.05% of the company's total share capital.

The second part of the programme, of also DKK 500m, is expected to take place from 1 October, 2014 to 30 September, 2015.

For further information, please contact

Investors and analysts

Lene Skole
Executive Vice President, CFO
Tel. +45 4911 1700

Ian S.E. Christensen
Vice President, Investor Relations
Tel. +45 4911 1800/+45 4911 1301
Email: dkisec@coloplast.com

Nick Fridberg
Sr. Investor Relations Manager
Tel. +45 4911 1800/+45 4911 1456
Email: dknf@coloplast.com

Press and the media

Ulla Lundhus
Head of Media and Positioning
Tel. +45 4911 1929
Email: dkul@coloplast.com

This announcement is available in a Danish and an English-language version.
In the event of discrepancies, the Danish version shall prevail.

The Coloplast logo is a registered trademark of Coloplast A/S. © 2014-04 All rights reserved Coloplast A/S, 3050 Humlebæk, Denmark.

Coloplast develops products and services that make life easier for people with very personal and private medical conditions. Working closely with the people who use our products, we create solutions that are sensitive to their special needs. We call this intimate healthcare.

Our business includes Ostomy Care, Urology Care, Continence Care and Wound and Skin Care. We operate globally and employ more than 8,500 people.